Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Quinn

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
European Journal of Radiology Open|September 12, 2022
Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinomaBino Varghese, Steven Cen, Haris Zahoor, et al.
Plos One|August 23, 2014
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladderXiuqing Li, Wesley W Choi, Rui Yan, et al.
Blood Neoplasia|January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomasJulio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Perioperative Medicine (London, England)|March 3, 2026
The feasibility of implementing and evaluating individualised digital prehabilitation prior to major elective surgery in adults aged ≥ 50 years: the PreActiv interventionAnnabelle Emery, Rebecca Allam, David Quinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, NeratinibGary A Ulaner, Cristina Saura, Sarina A Piha-Paul, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerStuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, et al.
Cancer Chemotherapy and Pharmacology|November 28, 2025
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancerStuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial CarcinomaSarmad Sadeghi, David Quinn, Tanya Dorff, et al.
JAMIA Open|November 21, 2025
The AIR·MS data platform for artificial intelligence in healthcarePablo Guerrero, Morten Ernebjerg, Thomas Holst, et al.
Blood Advances|March 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisJohn O Mascarenhas, Laura Maria Fogliatto, Steven D Green, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
European Journal of Radiology Open|September 12, 2022
Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinomaBino Varghese, Steven Cen, Haris Zahoor, et al.
Plos One|August 23, 2014
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladderXiuqing Li, Wesley W Choi, Rui Yan, et al.
Blood Neoplasia|January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomasJulio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Perioperative Medicine (London, England)|March 3, 2026
The feasibility of implementing and evaluating individualised digital prehabilitation prior to major elective surgery in adults aged ≥ 50 years: the PreActiv interventionAnnabelle Emery, Rebecca Allam, David Quinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, NeratinibGary A Ulaner, Cristina Saura, Sarina A Piha-Paul, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerStuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, et al.
Cancer Chemotherapy and Pharmacology|November 28, 2025
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancerStuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial CarcinomaSarmad Sadeghi, David Quinn, Tanya Dorff, et al.
JAMIA Open|November 21, 2025
The AIR·MS data platform for artificial intelligence in healthcarePablo Guerrero, Morten Ernebjerg, Thomas Holst, et al.
Blood Advances|March 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisJohn O Mascarenhas, Laura Maria Fogliatto, Steven D Green, et al.
Pageof 8